Marburg hemorrhagic fever overview

Jump to navigation Jump to search

Marburg hemorrhagic fever Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Marburg hemorrhagic fever from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Future or Investigational Therapies

Case Studies

Case #1

Marburg hemorrhagic fever overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Marburg hemorrhagic fever overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Marburg hemorrhagic fever overview

CDC on Marburg hemorrhagic fever overview

Marburg hemorrhagic fever overview in the news

Blogs on Marburg hemorrhagic fever overview

Directions to Hospitals Treating Marburg hemorrhagic fever

Risk calculators and risk factors for Marburg hemorrhagic fever overview

Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.

Overview

The Marburg virus causes severe viral hemorrhagic fever in humans with case fatality rates ranging from 24% to 88%. [1] Rousettus aegypti, fruit bats of the Pteropodidae family, are considered to be natural hosts of Marburg virus. The Marburg virus is transmitted to people from fruit bats and spreads through human-to-human transmission. No specific antiviral treatment or vaccine is available.

Historical Perspective

Marburg hemorrhagic fever was first detected in 1967 in Marburg after which there has been reports of several sporadic outbreaks all over the world. Subsequently, outbreaks and sporadic cases were reported in Angola, Democratic Republic of the Congo, Kenya, South Africa, and Uganda

Classification

Pathophysiology

Marburg virus is the causative agent of Marburg haemorrhagic fever (MHF). Initial human infection results from prolonged exposure to mines or caves inhabited by Rousettus bat colonies. After the Marburg virus initially transfers from animal host to human, mode of transmission is usually human-to-human and results from direct contact with bodily fluids of infected persons (blood, secretions) other contact fomites contaminated with infectious blood and tissues. Marburg virus primarily infects macrophages and dendritic cells. A cascade of events leads to Hypotension, metabolic disorders, immunosuppression and coagulopathy, finally resulting in multiorgan failure and shock.

Causes

Marburg virus (/ˈmɑːrbərɡ ˈvrəs/ Template:Respell Template:Respell[2]) is a hemorrhagic fever virus of the Filoviridae family of viruses and a member of the species Marburg marburgvirus, genus Marburgvirus. Marburg virus (MARV) causes Marburg virus disease in humans and nonhuman primates, a form of viral hemorrhagic fever.[3] The virus is considered to be extremely dangerous. The WHO rates it as a Risk Group 4 Pathogen (requiring biosafety level 4-equivalent containment).[4] In the United States, the NIH/National Institute of Allergy and Infectious Diseases ranks it as a Category A Priority Pathogen[5] and the Centers for Disease Control and Prevention lists it as a Category A Bioterrorism Agent.[6] It is also is listed as a biological agent for export control by the Australia Group.[7]

In 2009, expanded clinical trials of an Ebola and Marburg vaccine began in Kampala, Uganda.[8][9]

Differentiating Marburg hemorrhagic fever from Other Diseases

Marburg hemorrhagic fever must be differentiated from other viral hemorrhagic fevers that may cause fever, abdominal pain,and bleeding such as Ebola, Crimean-Congo hemorrhagic fever (CCHF), Hantavirus Infection, Rift Valley fever, Lujo hemorrhagic fever and Lassa fever. Because many of the signs and symptoms of Marburg hemorrhagic fever are similar to those of other infectious diseases such as malaria or typhoid fever, leptospirosis, Marburg hemorrhagic fever must also be differentiated from those infections.

Epidemiology and Demographics

Recorded cases of Marburg hemorrhagic fever disease are rare. The first documented outbreak of marburg hemorrhagic fever occurred in 1967 in Marburg and Frankfurt, Germany and in Belgrade. Case fatality rates in marburg hemorrhagic fever outbreaks have ranged from 23% to 90%. Marburg hemorrhagic fever commonly affects younger individuals less than 5 years old and adults >50 years old compared to normal age groups.

Risk Factors

Common risk factors in the development of Marburg hemorrhagic fever include close contact with African fruit bats, human patients, or non-human primates infected with Marburg virus. Less common risk factors in the development of Marburg hemorrhagic fever include occupations (people who handle non-human primates from Africa) and travellers to endemic areas.

Screening

There is insufficient evidence to recommend routine screening for Marburg hemorrhagic fever.

Natural History, Complications, and Prognosis

If left untreated symptoms of marburg hemorrhagic fever become increasingly severe and can include jaundice, inflammation of the pancreas, severe weight loss, delirium, shock, liver failure, massive hemorrhage, and multi-organ dysfunction. Common complications of marburg hemorrhagic fever include orchitis, Transverse myelitis and Parotitis. Prognosis of marburg hemorrhagic fever is generally poor. Case fatality rates in marburg hemorrhagic fever outbreaks have ranged from 23% to 90%.

Diagnosis

Diagnostic Criteria

The diagnosis of Marburg hemorrhagic fever relies primarily on the laboratory techniques such as reverse transcriptase PCR and ELISA-based antigen and antibody detection.

History and Symptoms

Marburg hemorrhagic fever initially appears as a nonspecific febrile illness, which then rapidly progresses and leads to hemorrhagic complications and in severe cases may lead to a septic shock-like syndrome.

Physical Examination

Laboratory Findings

Marburg virus infection may be confirmed by the laboratory techniques such as antibody-capture enzyme-linked immunosorbent assay, antigen-capture detection tests, serum neutralization test, reverse-transcriptase polymerase chain reaction (RT-PCR), Antigen detection tests and virus isolation by cell culture.

Electrocardiogram

X-ray

Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

There has been no approved treatment regimen yet for Marburg virus disease. However, few of the treatment modalities such as blood component therapy, immune therapy, and drug therapy are currently being evaluated. Supportive care such as rehydration with oral or intravenous fluids and maintenance of electrolyte balance, analgesics and symptomatic treatment may be beneficial.

Surgery

Surgical intervention is not recommended for the management of Marburg hemorrhagic fever.

Primary Prevention

No specific treatment or vaccine is yet available for Marburg hemorrhagic fever. Several vaccine candidates are being tested but it could be several years before any are available. New drug therapies have shown promising results in laboratory studies and are currently being evaluated. One way to protect against infection is avoiding fruit bats, and sick non-human primates in central Africa. Reducing the risk of infection to people include reducing the risk of bat-to-human transmission as well as human-to-human transmission, health education and, outbreak containment measures.

Secondary Prevention

Effective measures for the secondary prevention of transmission Marburg hemorrhagic fever from person-to-person include barrier nursing techniques (wearing of protective gowns, gloves, and masks, placing the infected individual in strict isolation, sterilization or proper disposal of needles, equipment, and patient excretions).

References

  1. http://www.who.int/mediacentre/factsheets/fs_marburg/en/
  2. Spickler, Anna. "Ebolavirus and Marburgvirus Infections" (PDF).
  3. US Department of Health and Human Services. "Biosafety in Microbiological and Biomedical Laboratories (BMBL) 5th Edition". Retrieved 2011-10-16.
  4. "Biodefense and Emerging Infectious Diseases". US National Institute of Allergy and Infectious Diseases (NIAID), US National Institutes of Health (NIH). Retrieved 2011-10-16.
  5. US Centers for Disease Control and Prevention (CDC). "Bioterrorism Agents/Diseases". Retrieved 2011-10-16.
  6. The Australia Group. "List of Biological Agents for Export Control". Retrieved 2011-10-16.
  7. Beth Skwarecki Ebola, Marburg DNA Vaccines Prove Safe in Phase 1 Trial Medscape Medical News, September 17, 2014
  8. Evaluating an Ebola and a Marburg Vaccine in Uganda U.S. Department of Health & Human Services